RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00035024.xml
PDF herunterladen
Thromb Haemost 2017; 117(02): 422-425
DOI: 10.1160/TH16-06-0451
DOI: 10.1160/TH16-06-0451
Letters to the Editor
Antithrombin is not protective against renal ischaemia-reperfusion injury
Authors
Financial support: This work was supported by a research grant from the Agence Nationale de la Recherche (no. ANR-2011-RPIB-018). Y. B. received funding from CORRDIM (Cardiovasculaire Obésité Rein Diabète – Domaine d’Intérêt Majeur). A.-L. M. received a grant for one year (2014–2015) from the Laboratoire français du Fractionnement et des Biotechnologies.
Weitere Informationen
Publikationsverlauf
Received:15. Juni 2016
Accepted after major revision:06. Oktober 2016
Publikationsdatum:
01. Dezember 2017 (online)
-
References
- 1 Souter PJ, Thomas S, Hubbard AR. et al. Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood. Crit Care Med 2001; 29: 134-139.
- 2 Dunzendorfer S, Kaneider N, Rabensteiner A. et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood 2001; 97: 1079-1085.
- 3 Harada N, Okajima K, Uchiba M. et al. Antithrombin reduces ischemia/reperfusion-induced liver injury in rats by activation of cyclooxygenase-1. Thromb Haemost 2004; 92: 550-558.
- 4 Schoots IG, Levi M, van Vliet AK. et al. Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit Care Med 2004; 32: 1375-1383.
- 5 Wang J, Wang Y, Wang J. et al. Antithrombin is protective against myocardial ischemia and reperfusion injury. J Thromb Haemost 2013; 11: 1020-1028.
- 6 Minnema MC, Chang ACK, Jansen PM. et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117-1123.
- 7 Dickneite G. A comparison of the pharmacokinetics of antithrombin derived from human plasma and from transgenic goats and the prevention of sepsis in an animal model. Biopharm Drug Dispos 2008; 29: 356-365.
- 8 Warren BL, Eid A, Singer P. et al. High-dose antithrombin iii in severe sepsis: A randomized controlled trial. J Am Med Assoc 2001; 286: 1869-1878.
- 9 Retractions. Mizutani A, Okajima K, Uchiba M, Noguchi TActivated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95: 3781-3787and Mizutani A, Okajima K, Uchiba M, et al. Antithrombin reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 2003; 101: 3029-3036 Blood 2013; 122: 302.
- 10 Dong W, Wang H, Shahzad K. et al. Activated Protein C Ameliorates Renal Ischemia-Reperfusion Injury by Restricting Y-Box Binding Protein-1 Ubiquitination. J Am Soc Nephrol 2015; 26: 2789-2799.
- 11 Sabbisetti VS, Ito K, Wang C. et al. Novel assays for detection of urinary KIM-1 in mouse models of kidney injury. Toxicol Sci Off J Soc Toxicol 2013; 131: 13-25.
- 12 European Medicines Agency Product information - ATryn available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000587/WC500028260.pdf
- 13 Compendium Suisse des Médicaments®. Information professionnelle - Kybernin® P available at: https://compendium.ch/mpro/mnr/21594/html/fr
- 14 Agence Nationale de Sécurité du Médicament et des Produits de Santé. Résumé des caractéristiques du produit - Aclotine available at: http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0137874.htm#Rcp_6_1_ListeExcipients
- 15 Zhong X, Li X, Qian L. et al. Glycine attenuates myocardial ischemia-reperfusion injury by inhibiting myocardial apoptosis in rats. J Biomed Res 2012; 26: 346-354.
- 16 Lu Y, Zhang J, Ma B. et al. Glycine attenuates cerebral ischemia/reperfusion injury by inhibiting neuronal apoptosis in mice. Neurochem Int 2012; 61: 649-658.
- 17 Petrat F, Drowatzky J, Boengler K. et al. Protection from glycine at low doses in ischemia-reperfusion injury of the rat small intestine. Eur Surg Res 2011; 46: 180-187.
- 18 Duru S, Koca U, Oztekin S. et al. Antithrombin III pretreatment reduces neutrophil recruitment into the lung and skeletal muscle tissues in the rat model of bilateral lower limb ischemia and reperfusion: a pilot study. Acta Anaesthesiol Scand 2005; 49: 1142-1148.
- 19 Zambas NA, Karkos CD, Kambaroudis AG. et al. Protective effect of antithrombin III against lung and myocardial injury in lower-limb ischemia-reperfusion syndrome. Ann Vasc Surg 2012; 26: 566-570.
- 20 Bianchini EP, Fazavana J, Picard V. et al. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood 2011; 117: 2054-2060.
- 21 Bock F, Shahzad K, Wang H. et al. Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci USA 2013; 110: 648-653.
- 22 Chang WS, Harper PL. Commercial antithrombin concentrate contains inactive L-forms of antithrombin. Thromb Haemost 1997; 77: 323-328.
- 23 Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999; 94: 3388-3396.
- 24 Heger A, Grunert T, Schulz P. et al. Separation of active and inactive forms of human antithrombin by heparin affinity chromatography. Thromb Res 2002; 106: 157-164.
- 25 Marie A-L, Tran NT, Saller F. et al. A capillary zone electrophoresis method to detect conformers and dimers of antithrombin in therapeutic preparations.Electrophoresis 2016 Mar 16. doi: 10.1002/elps.201500456.